Literature DB >> 23831944

Protective role of NAD(P)H:quinone oxidoreductase 1 (NQO1) in cisplatin-induced nephrotoxicity.

Gil-Tae Gang1, Yong-Hoon Kim, Jung-Ran Noh, Kyoung-Shim Kim, Ju-Young Jung, Minho Shong, Jung Hwan Hwang, Chul-Ho Lee.   

Abstract

Although cisplatin is widely used as an anti-cancer agent, its use is significantly limited because of its tendency to induce nephrotoxicity through poorly understood mechanisms. NAD(P)H:quinone oxidoreductase 1 (NQO1) is well known to regulate ROS generation. The purpose of this study was to investigate whether NQO1 modulates cisplatin-induced renal failure associated with NADPH oxidase (NOX)-derived ROS production in an animal model. NQO1-/- mice were treated with cisplatin (18 mg/kg) and renal function, oxidative stress, and tubular apoptosis were assessed. NQO1-/- mice showed increased blood urea nitrogen and creatinine levels, tubular damage, oxidative stress, and apoptosis. In accordance with these results, the cellular NADPH/NADP ratio and NOX activity were markedly increased in the kidneys of NQO1-/- mice compared to NQO1+/+ mice. In addition, activation of NQO1 by βL treatment significantly improved renal dysfunction and reduced tubular cell damage, oxidative stress, and apoptosis. This study demonstrates that NQO1 protects cells against renal failure induced by cisplatin, and that this effect is mediated by decreased NOX activity via cellular NADPH/NADP modulation. These results provide convincing evidence that NQO1 might be beneficial for ameliorating renal failure induced by cisplatin.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cisplatin; NADPH oxidase; NQO1; β-lapachone

Mesh:

Substances:

Year:  2013        PMID: 23831944     DOI: 10.1016/j.toxlet.2013.06.239

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.271


  13 in total

1.  Integrated transcriptomic and proteomic analyses uncover regulatory roles of Nrf2 in the kidney.

Authors:  Luke M Shelton; Adam Lister; Joanne Walsh; Rosalind E Jenkins; Michael H L Wong; Cliff Rowe; Emanuele Ricci; Lorenzo Ressel; Yongxiang Fang; Philippe Demougin; Vanja Vukojevic; Paul M O'Neill; Christopher E Goldring; Neil R Kitteringham; B Kevin Park; Alex Odermatt; Ian M Copple
Journal:  Kidney Int       Date:  2015-09-30       Impact factor: 10.612

2.  Augmentation of NAD(+) by NQO1 attenuates cisplatin-mediated hearing impairment.

Authors:  H-J Kim; G-S Oh; A Shen; S-B Lee; S-K Choe; K-B Kwon; S Lee; K-S Seo; T H Kwak; R Park; H-S So
Journal:  Cell Death Dis       Date:  2014-06-12       Impact factor: 8.469

3.  Protective Effects of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, against Cisplatin-Induced Nephrotoxicity in Mice.

Authors:  Seung Hee Choi; Jaechan Leem; In-Kyu Lee
Journal:  Mediators Inflamm       Date:  2017-11-28       Impact factor: 4.711

4.  NAD+ augmentation ameliorates acute pancreatitis through regulation of inflammasome signalling.

Authors:  AiHua Shen; Hyung-Jin Kim; Gi-Su Oh; Su-Bin Lee; Seung Hoon Lee; Arpana Pandit; Dipendra Khadka; Seong-Kyu Choe; Sung Chul Kwak; Sei-Hoon Yang; Eun-Young Cho; Hyun-Seok Kim; Hail Kim; Raekil Park; Tae Hwan Kwak; Hong-Seob So
Journal:  Sci Rep       Date:  2017-06-07       Impact factor: 4.379

5.  Catalytic competence, structure and stability of the cancer-associated R139W variant of the human NAD(P)H:quinone oxidoreductase 1 (NQO1).

Authors:  Wolf-Dieter Lienhart; Emilia Strandback; Venugopal Gudipati; Karin Koch; Alexandra Binter; Michael K Uhl; David M Rantasa; Benjamin Bourgeois; Tobias Madl; Klaus Zangger; Karl Gruber; Peter Macheroux
Journal:  FEBS J       Date:  2017-03-17       Impact factor: 5.542

6.  Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance.

Authors:  David P Hill; Akeena Harper; Joan Malcolm; Monica S McAndrews; Susan M Mockus; Sara E Patterson; Timothy Reynolds; Erich J Baker; Carol J Bult; Elissa J Chesler; Judith A Blake
Journal:  BMC Cancer       Date:  2019-11-04       Impact factor: 4.430

7.  Formononetin protects against cisplatin‑induced acute kidney injury through activation of the PPARα/Nrf2/HO‑1/NQO1 pathway.

Authors:  Yan Hao; Jie Miao; Wenjia Liu; Li Peng; Yue Chen; Qing Zhong
Journal:  Int J Mol Med       Date:  2020-12-01       Impact factor: 4.101

Review 8.  Functions of NQO1 in Cellular Protection and CoQ10 Metabolism and its Potential Role as a Redox Sensitive Molecular Switch.

Authors:  David Ross; David Siegel
Journal:  Front Physiol       Date:  2017-08-24       Impact factor: 4.566

9.  Protective effects of Tat-NQO1 against oxidative stress-induced HT-22 cell damage, and ischemic injury in animals.

Authors:  Hyo Sang Jo; Duk-Soo Kim; Eun Hee Ahn; Dae Won Kim; Min Jea Shin; Su Bin Cho; Jung Hwan Park; Chi Hern Lee; Eun Ji Yeo; Yeon Joo Choi; Hyeon Ji Yeo; Christine Seok Young Chung; Sung-Woo Cho; Kyu Hyung Han; Jinseu Park; Won Sik Eum; Soo Young Choi
Journal:  BMB Rep       Date:  2016-11       Impact factor: 4.778

10.  The potential roles of NAD(P)H:quinone oxidoreductase 1 in the development of diabetic nephropathy and actin polymerization.

Authors:  Sung-Je Moon; Jin Young Jeong; Jae-Hoon Kim; Dong-Hee Choi; Hyunsu Choi; Yoon-Kyung Chang; Ki Ryang Na; Kang Wook Lee; Chul-Ho Lee; Dae Eun Choi; Jung Hwan Hwang
Journal:  Sci Rep       Date:  2020-10-20       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.